- Survival Benefit of Antiviral Agents for Hepatocellular Carcinoma Patients Treated with Sorafenib
-
Jeong Han Kim, Hyung Min Yu, Yong Hwang, Soon Young Ko, Won Hyeok Choe, So Young Kwon
-
J Liver Cancer. 2016;16(1):23-30. Published online March 31, 2016
-
DOI: https://doi.org/10.17998/jlc.16.1.23
-
-
Abstract
PDF
- Background/Aim
s: Nucleos(t)ide analogues (NAs) help reduce the recurrence rate after
the curative treatment of hepatitis B related hepatocellular carcinoma (HCC). Sorafenib has
been shown to improve survival of advanced HCC patients. Whether antiviral therapy with
NAs could help such patients is unknown. Our aim is to investigate the usefulness of antiviral
therapy for advanced-stage HCC treated with sorafenib.
Methods We performed a retrospective cohort study in advanced-stage HCC patients
treated with sorafenib between June 2007 and December 2013. Patients in group A (the nonantiviral
therapy group) were treated with sorafenib alone. Those in group B (the antiviral
therapy group) were treated with sorafenib and NAs. Progression-free survival (PS) and overall
survival (OS) were compared between these two groups.
Results Finally, 23 patients in group A and 40 patients in group B were enrolled in the study.
The mean number of days of treatment with sorafenib was 79 (34-231) days and 96 (33-449)
days for group A and B, respectively (P=0.286). The mean PS of group A and B was 97 (14-449)
days and 51 (0-461) days, respectively (P=0.068). The OS was 154 (44-741) days in group A and
138 (30-1,025) days in group B (P=0.665). PS and OS showed no significant difference between
the two groups.
Conclusions This study shows that there was no significant survival gain of using antiviral
therapy in patients with advanced-stage HCC treated with sorafenib. In consideration of costeffectiveness,
antiviral therapy may be not mandatory. (J Liver Cancer 2016;16:23-30)
- A Case of Hepatocellular Carcinoma with Improved Decompansated Liver Cirrhosis with Combination Treatment of Transarterial Chemoembolization and Radiofrequency Ablation
-
Hyung Min Yu, Won Hyeok Choe, So Young Kwon, Jeong Han Kim
-
J Liver Cancer. 2014;14(2):131-134. Published online September 30, 2014
-
DOI: https://doi.org/10.17998/jlc.14.2.131
-
-
Abstract
PDF
- A 54-year-old female patient with no medical history visited our hospital complaining of both
pretibial pitting oedema for 6 months, and abdominal distension for 1 month. Computed
tomography and magnetic resonance imaging revealed an 2.3cm sized tumour at segment
2 of the liver. Her Child-Turcotte-Pugh (CTP) class was C (score 11) at the initial visit. She was
diagnosed as hepatocellular carcinoma (UICC stage II, BCLC stage D), and then she underwent
conservative treatment for 1 month. After one month of conservative treatment, her liver
function was improved to CTP class B (score 8), and then she underwent combination
treatment of transarterial chemoembolization and radiofrequency ablation. However, her
liver function was deteriorated gradually. She was transferred to other hospital for liver
transplantation eventually. (J Liver Cancer 2014;14:131-134)
|